Who are Prozac's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sarcosine and SSRI, YM443, Lexapro, Paxil-CR, oral escitalopram, Sertraline [Zoloft].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluoxetine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Prozac — Competitive Intelligence Brief

Prozac (fluoxetine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective Serotonin Reuptake Inhibitor (SSRI). Area: Neuroscience.

marketed Selective Serotonin Reuptake Inhibitor (SSRI) Serotonin reuptake transporter Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Prozac (fluoxetine) — Eli Lilly and Company. Fluoxetine inhibits CNS neuronal uptake of serotonin, though exact mechanism unknown.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Prozac TARGET	fluoxetine	Eli Lilly and Company	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin reuptake transporter	1987-12-29
Sarcosine and SSRI	Sarcosine and SSRI	All India Institute of Medical Sciences, Bhubaneswar	marketed	GlyT1 inhibitor + SSRI combination	Glycine transporter-1 (GlyT1); serotonin reuptake transporter (SERT)
YM443	YM443	Astellas Pharma Inc	phase 3	SSRI	Serotonin reuptake transporter
Lexapro	escitalopram	Generic (originally Lundbeck/Forest)	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin (5-HT) reuptake transporter	2002-08-14
Paxil-CR	Paxil-CR	University of Oklahoma	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
oral escitalopram	oral escitalopram	NYU Langone Health	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Sertraline [Zoloft]	Sertraline [Zoloft]	Johns Hopkins University	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective Serotonin Reuptake Inhibitor (SSRI) class)

Eli Lilly and Company · 1 drug in this class
Generic (originally Lundbeck/Forest) · 1 drug in this class
Pfizer Inc. · 1 drug in this class
University of Pennsylvania · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prozac — Competitive Intelligence Brief. https://druglandscape.com/ci/fluoxetine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab